EHA 2019 | PRM-151 for myelofibrosis

Name: PRM-151 for myelofibrosis
Uploaded: 2019-06-15T00:00:00.000Z
Duration: 1 min 31 s
Description: Here, Srdan Verstovsek, MD, PhD, from the University of Texas MD Anderson Cancer Center, Houston, TX, presents updates on the Phase II study of PRM-151 for myelofibrosis patients previously treated with or are ineligible for treatment with ruxolitinib. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Srdan Verstovsek • 15 Jun 2019

EHA 2019

Myelofibrosis PRM-151 Ruxolitinib

Here, Srdan Verstovsek, MD, PhD, from the University of Texas MD Anderson Cancer Center, Houston, TX, presents updates on the Phase II study of PRM-151 for myelofibrosis patients previously treated with or are ineligible for treatment with ruxolitinib. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.